Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Sees Significant Decrease in Short Interest

Posted by Renee Jackson on Sep 16th, 2025

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC – Get Free Report) saw a significant decrease in short interest in August. As of August 31st, there was short interest totaling 12,100 shares, a decrease of 32.4% from the August 15th total of 17,900 shares. Currently, 1.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 31,100 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 31,100 shares, the short-interest ratio is currently 0.4 days. Currently, 1.7% of the shares of the stock are sold short.

Virtus LifeSci Biotech Clinical Trials ETF Stock Down 0.5%

NYSEARCA BBC opened at $24.00 on Tuesday. Virtus LifeSci Biotech Clinical Trials ETF has a 1 year low of $13.42 and a 1 year high of $31.65. The business’s fifty day moving average is $22.41 and its two-hundred day moving average is $19.87.

Virtus LifeSci Biotech Clinical Trials ETF Company Profile

(Get Free Report)

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.